Clinical Trial Update: Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ganciclovir to prevent cytomegalovirus reactivation in patients with acute respiratory failure and sepsis; the study was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Failure
• Sepsis

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Respiratory Failure | Phase 3 | Status: TERMINATED | Results posted: 2025-12-12